OASMIA PHARMACEUTICAL

COMPANY PRESENTATION

BIO-EUROPE, HAMBURG, GERMANY

NOVEMBER 2019

FORWARD LOOKING STATEMENT

IMPORTANT NOTICE:

The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

No representation or warranty expressed or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinion contained herein.

The information in this presentation may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

FORWARD LOOKING STATEMENTS:

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Although Oasmia believes that the expectations reflected in such forward looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors.

Important factors that may cause such a difference for Oasmia include, but are not limited to: (i) the macroeconomic development, (ii) change in the competitive climate and (iii) change in interest rate level.

This presentation does not imply that Oasmia has undertaken to revise these forward-looking statements, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.

CORPORATE OVERVIEW

We are an innovation-focused pharmaceutical company
specialising in human and animal oncology

HQ Uppsala, Sweden
Subsidiaries in USA,
Hong Kong and Moscow

NASDAQ Stockholm 2010
Frankfurt Stock Exchange 2011

60 employees

FDA and EMA approved production facility in Sweden

ADVANCING DRUG DELIVERY IN CANCER

The challenge:
Solve the insoluble

Many cancer APIs are not water soluble:

- 40% of approved drugs
- 90% of developmental pipeline drugs[1]

Low bioavailability
Rapid elimination

Carriers optimize delivery, but bring unpredictable pharmacokinetics and significant AEs

Managing toxicity means premedication and longer infusion times

AE, adverse event; API, active pharmaceutical ingredient; PK: pharmacokinetics.

1. Kalepu S, Nekkanti V. Acta *Pharmaceutical Sinica* B; 2015: 442-453. https://doi.org/10.1016/j.apsb.2015.07.003

TECHNOLOGY PLATFORM

Active Pharmaceutical Ingredient (API)

Water-insoluble

XR17 molecule

Hydrophilic, polar head
Hydrophobic, non polar chain

Micelle consisting of XR17 and API



Water soluble

XR17 MOLECULE

Micellar delivery:
A safe way to provide APIs

In house invention
& development

Based on novel
vitamin A derivative

✓ Clinical studies
✓ Toxicological studies

Key benefits:

- Improved solubility
- Improved bioavailability
- Avoid toxic solvents

Shorter
infusion time

No mandatory need for
pre-medication with
immunosuppressants

API, active pharmaceutical ingredient

WIDE PATENT PROTECTION TO 2036

XR17 is protected
by the following patent families

"Process"

Protects the manufacturing process for XR17

to: December **2036**

PCT application granted

3 patents granted
in US, ZA

Application pending in Eurasia, EPO, AU, CA, CN, HK, IN, ID, JP, MY, MX, NZ, KR, SG and UA

"Water-insoluble"

Protects poorly water-soluble APIs in combination with XR17

to: December **2028**

57 patents granted
across Eurasia, EPO, AU, CA, CN, JP, KR, MX, MY, NZ, UA, US, ZA

SPC (5-year extension) applied for in the EU, pending

"Anticancer compositions"

Protects XR17 in combination with chemotherapeutic agents

to: November **2022**

6 patents granted
In US, FR, UK, DE, CN and HK

API, active pharmaceutical ingredient

LAUNCH MARKET

Ovarian cancer:
A strong and stable market for taxane chemotherapy

Prevalence of OC per year

>22,000 [USA]; >27,000 [EU top 5][1]

Growth of market

- Expected value increase 12% YoY until 2025 [1]
- Growth driven by innovative treatments e.g. PARP inhibitors [for specific subtypes of patients only i.e. BRCA mutated – 10% of patients][2]

Most patients treated with chemotherapy backbone

- 1st line paclitaxel-carboplatin therapy is a standard treatment for newly diagnosed OC [2]
- 70% of patients relapse following 1st line paclitaxel-carboplatin therapy; re-challenging platinum-sensitive patients with carboplatin-doublet is ESMO strategy of choice [2]

1. Grand View Research, Ovarian Cancer Drug Market 2019
2. Annals of Oncology 30: 672–705, 2019, ESMO guidelines. doi:10.1093/annonc/mdz062 Published online 2 May 2019

PROOF OF CONCEPT

APEALEA: Micellar formulation of paclitaxel based on XR17

Primary endpoint:
Progression free survival (PFS) per RECIST

Secondary endpoint: Overall survival (OS)



Premedication not mandatory in Apealea arm

Randomized, open label, multicenter study comparing efficacy and safety of Apealea and solvent-based paclitaxel (Taxol®).
Patients had recurrent epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer and had relapsed ≥6 months after platinum-containing treatment.
Study took place at 16 countries at 81 centres in Europe including Russia (44%); Belarus (14%) and Ukraine (13%).

PROOF OF CONCEPT

APEALEA: Micellar formulation of paclitaxel based on XR17

As effective and safe as solvent-based paclitaxel[1] :

- Proven non-inferiority [Apealea 10.3 months PFS vs 10.1 months]
- Apealea had a similar safety profile to solvent-based paclitaxel at significantly higher dose and numerically fewer neuropathies

Approvals
Central EMA approval Nov 2018, Russia 2015, Kazakhstan 2017
USA: Submission planned for 2020

Manufacturing
Apealea and XR17 secured by in-house capacities as well as with a CMO agreement with Baxter Oncology, Germany

1. Apealea Summary of Product Characteristics. www.ema.europa.eu

WHEN THE CARRIER IS THE BARRIER

APEALEA:

For women who need an alternative to solvent-based paclitaxel

Initial Positioning:

For women with first relapse of platinum-sensitive epithelial ovarian cancer, Apealea provides a **treatment alternative** to solvent-based paclitaxel **without the risk of unwanted toxicity** from cremophor-EL as well as the opportunity to avoid **excessive usage of corticosteroids** as premedication.

Indicated in combination with carboplatin for the treatment of adult patients with first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer[1]

1. Apealea Summary of Product Characteristics. www.ema.europa.eu

THE WAY FORWARD

Next steps
for Apealea

Establish commercial partnerships through licensing and/or distribution

Launch Apealea in Europe in selective countries i.e. Nordics, through a co-promotion model

Apply for marketing authorization in the USA and China within 2020

Establish scientific partnerships to further expand in oncology

EXECUTIVE SUMMARY / INVESTMENT HIGHLIGHTS

Our strong value proposition
makes Oasmia an attractive investment opportunity

1

Global market opportunity

Oncology market estimated to reach USD 176 billion by 2025[1]

2

Dynamic Management Team

Highly experienced BoD, Scientific and Business Advisory Boards

3

Proprietary technology platform

XR17:
Broad Applicable technology

4



Proof of concept

Late-stage asset Apealea (Paclical) approved in EES & Russia

5

Strong commercial partnerships

Global opportunities for commercialization

1. Allied Market Research. Cancer Drugs Market 2019. www.alliedmarketresearch.com

oasmia

For more information visit
www.oasmia.com
or send an email to
business.development@oasmia.com